Lorcaserin
- TRADE NAME: Belviq (Eisai)
- INDICATIONS: Obesity in adults who have at least one weight-related health condition, such as high blood pressure, Type II diabetes, or high cholesterol
- CLASS: Serotonin receptor agonist
- HALF-LIFE: ~11 hours
FDA APPROVAL DATE: 06/27/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Antipsychotics, Bupropion, Dextromethorphan, Lithium, MAO inhibitors, SNRIs, SSRIs, St John's Wort, Tramadol, Tricyclic antidepressants, Triptans
PREGNANCY CATEGORY: X
On 2/13/2020, the U.S. Food and Drug Administration (FDA) requested that the manufacturer of lorcaserin (Belviq) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
